Has Prasugrel Been Compared Correctly With Clopidogrel in Non–ST-Segment Elevation Acute Coronary Syndrome?  by Lozano, Iñigo et al.
Letters J A C C V O L . 6 5 , N O . 1 6 , 2 0 1 5
A P R I L 2 8 , 2 0 1 5 : 1 7 1 0 – 9
1716*First Department of Cardiology
Hippokration General Hospital
114 Vas. Soﬁas Avenue
Athens 11527
Greece
E-mail: ktoutouz@gmail.com
http://dx.doi.org/10.1016/j.jacc.2015.01.055RE F E RENCE S
1. Hannan E, Zhong Y, Walford G, et al. Coronary artery bypass graft surgery
versus drug-eluting stents for patients with isolated proximal left anterior
descending disease. J Am Coll Cardiol 2014;64:2717–26.
2. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with
drug-eluting and bare-metal coronary stents: a mixed-treatment comparison
analysis of 117 762 patient-years of follow-up from randomized trials. Circu-
lation 2012;125:2873–91.
3. Benedetto U, Raja S, Soliman R, et al. Minimally invasive direct coronary
artery bypass improves late survival compared with drug-eluting stents in
isolated proximal left anterior descending artery disease: a 10-year follow-up,
single-center, propensity score analysis. J Thorac Cardiovasc Surg 2014;148:
1316–22.
4. Toutouzas K, Patsa C, Vaina S, et al. Drug eluting stents versus coronary
artery bypass surgery in patients with isolated proximal lesion in left anterior
descending artery suffering from chronic stable angina. Catheter Cardiovasc
Interv 2007;70:832–7.
5. Blazek S, Holzhey D, Jungert C, et al. Comparison of bare-metal stenting
with minimally invasive bypass surgery for stenosis of the left anterior
descending coronary artery: 10-year follow-up of a randomized trial. J Am
Coll Cardiol Intv 2013;6:20–6.REPLY: Is CABG Superior to DES for Repeat
Revascularization in Patients With Isolated
Proximal LAD Disease?We thank Dr. Matsoukis and colleages for their letter
expressing an interest in our recent study (1).
Regarding the type of drug-eluting stents (DES)
(ﬁrst vs. second generation), 72% of the stents used in
the propensity-matched DES/coronary artery bypass
graft (CABG) pairs were second-generation DES, with
the others being ﬁrst-generation DES. When the pairs
were limited to second-generation DES compared
with CABG surgery, there were still no signiﬁcant
differences for mortality or for mortality/myocardial
infarction/stroke. Repeat revascularization rates were
again lower for CABG surgery, and the adjusted haz-
ard ratio (AHR) was very similar to the AHR for all
pairs (0.60 vs. 0.54 for all pairs).
It is possible that our results could have been
different if we had used cardiac mortality instead of
all-cause mortality, but unfortunately we did not
have access to that measure.
It is not true that CABG surgery was associated
with a signiﬁcantly lower rate when we looked at the
composite endpoint of mortality/myocardial infarc-
tion/stroke. As the letter states, we found the AHR tobe 0.96 (95% conﬁdence interval: 0.86 to 1.06),
which is not signiﬁcant because the conﬁdence
interval includes the number 1.*Edward L. Hannan, PhD
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Compared Correctly With
Clopidogrel in Non–ST-
Segment Elevation Acute
Coronary Syndrome?We read with great interest the paper by Montalescot
et al. (1) and the editorial by Ibanez and Dangas (2)
about prasugrel in non–ST-segment myocardial in-
farction (NSTEMI), and we appreciate the research on
this interesting issue. The ACCOAST (A Comparison of
Prasugrel at PCI or Time of Diagnosis of Non-ST
Elevation Myocardial Infarction) trial demonstrated
that pre-treatment with prasugrel in NSTEMI adds no
beneﬁt compared with initiating the drug after angi-
ography and also was associated with an increase in
bleeding events (3). In the same way, in the subgroup
of patients analyzed in the ACCOAST-PCI, the results
are concordant with the main study in terms of same
clinical outcome as well as a higher rate of bleeding
events (1).
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1717As is pointed out in the editorial, both the recent
American College of Cardiology/American Heart
Association and the European Society of Cardiology
guidelines recommend prasugrel in NSTEMI only
after angiography, and this fact places prasugrel as a
second-line agent. Although prasugrel showed beneﬁt
over clopidogrel in the TRITON (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition with Prasugrel), the design of the
trial was criticized due to the 300-mg loading dose of
clopidogrel and also the administration after angiog-
raphy instead of earlier, probably limiting the effect of
clopidogrel, the effect of which takes longer to act.
In our opinion, the right comparison between
prasugrel and clopidogrel in NSTEMI has still not
been carried out. If we review both the results of the
CREDO (Clopidogrel Maintaining Dosage in Acute
Coronary Syndrome After Drug Eluting Stent Im-
plantation) and ACCOAST, we can assume that the
best moment to initiate clopidogrel would be as soon
as possible after admission and just after the initial
angiography for prasugrel. Both drugs have theoret-
ical advantages such as an unrestricted spectrum of
patients (4,5), fewer bleeding events, more experience
with the drug, and lower cost of clopidogrel versus
more rapid onset and action, a reduction in nonfatal
coronary events and stent thrombosis, and avoiding
the administration of the drug in patients who would
need surgery once the anatomy is known for prasu-
grel. Although it is highly improbable that a prospec-
tive and adequately powered study will be designed
8 years after the publication of the TRITON trial and
with the presence of ticagrelor in the market, we
believe that the only way to have the correct answer
for prasugrel and clopidogrel in NSTEMI would be to
compare in ischemic and bleeding events the pre-
treatment with clopidogrel with the administration
of prasugrel after the initial angiography, and it would
probably be the only way for prasugrel to once again
become a ﬁrst-line treatment for these patients.*Iñigo Lozano, MD, PhD
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Esp Cardiol (in press).REPLY: Has Prasugrel Been Compared
Correctly With Clopidogrel in
Non–ST-Segment Elevation
Acute Coronary Syndrome?We thank Dr. Lozano and colleagues for their interest
in our paper. However, they misinterpret the results
of the ACCOAST (Comparison of Prasugrel at PCI or
Time of Diagnosis of Non-ST Elevation Myocardial
Infarction) and of the preceding trials. Placing the
new P2Y12 antagonists in general and prasugrel in
particular as a second-line treatment in non–ST-
segment elevation myocardial infarction (NSTEMI)
does not reﬂect the superiority demonstrated by
these new drugs over clopidogrel in 2 pivotal trials. It
does not comply with the current guidelines, espe-
cially for the patients undergoing percutaneous cor-
onary intervention, as both prasugrel and ticagrelor
have a class I recommendation, whereas clopidogrel
should be given “only when prasugrel or ticagrelor
are not available or are contraindicated” (1). So the
ﬁrst error is to believe that clopidogrel is still the gold
standard for the treatment of NSTEMI.
The second error is to believe that pre-treatment
with a P2Y12 antagonist is of beneﬁt to NSTEMI
patients. Pre-treatment is a treatment given to the
patients while they wait to undergo coronary angiog-
raphy. Although Dr. Lozano thinks that this is the right
thing to do with clopidogrel, it has never been vali-
dated by a randomized study. This question of clopi-
dogrel pre-treatment was not evaluated in the CURE
(Clopidogrel in Unstable Angina to Prevent Recurrent
Events) study because the majority of patients did not
have coronary angiography performed in this study. It
was also not addressed by the CREDO (Clopidogrel for
the Reduction of Events During Observation) study
because the coronary status of the majority of patients
was known at the time of randomization (2). No study
